Wolfgang Weninger
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Wolfgang Weninger has a total of 752 co-authors. Here are the top co-authors by number of shared publications:
- Georg Stary
CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria
27 shared publications - Johanna Strobl
Department of Dermatology, Medical University of Vienna, Vienna, Austria
23 shared publications - Adelheid Elbe-Bürger
Medical University of Vienna
22 shared publications - Lars Einar French
Department of Dermatology and Allergy University Hospital, LMU Munich Munich Germany
22 shared publications - Nina Zila
Department of Dermatology, Medical University of Vienna, Vienna, Austria
22 shared publications - René Reitermaier
Department of Dermatology, Medical University of Vienna, Vienna, Austria
22 shared publications
Latest Publications
- Open Access
- 13 November 2026
- Published by Osterreichische Akademie der Wissenschaften, Verlag in SKINdeep
- Vol. 2, e208593
Paraneoplastic skin diseases
Paraneoplastic skin diseases (PSD) comprise a heterogeneous group of dermatoses associated with internal malignancies but are not caused by direct infiltration of the skin by tumor cells themselves. Instead, they reflect tumor-driven systemic effects mediated by hormones, growth factors, cytokines, antigens, or immune responses. A true paraneoplastic relationship is most likely when the dermatosis develops shortly before, concurrently with, or shortly after the diagnosis of the malignancy, and when both conditions follow a parallel clinical course. In this review, we revisit the concept of paraneoplastic dermatoses and propose a pragmatic classification into high-risk cutaneous paraneoplasias and low-to-moderate risk cutaneous paraneoplasias, rather than relying on the traditional distinction between “obligatory” and “facultative” entities. Particular emphasis is placed on high-risk disorders, including acrokeratosis paraneoplastica (Bazex syndrome), erythema gyratum repens, necrolytic migratory erythema, paraneoplastic pemphigus/paraneoplastic autoimmune multiorgan syndrome, hypertrichosis lanuginosa acquisita, and selected acanthotic syndromes such as malignant acanthosis nigricans, tripe palms, and florid cutaneous papillomatosis. For each entity, we summarize the characteristic clinical presentation, common tumor associations, histopathologic clues, current concepts of pathogenesis, differential diagnoses, and therapeutic implications. We also briefly address selected low-to-moderate risk paraneoplastic dermatoses, including dermatomyositis as well as Sweet syndrome, pyoderma gangrenosum, and autoimmune bullous diseases. Recognition of PSD is of major clinical importance because cutaneous signs may precede the diagnosis of cancer and thus provide an opportunity for early detection of an otherwise occult malignancy. Close interdisciplinary collaboration among dermatologists, pathologists, oncologists, and other specialists is essential for accurate diagnosis, timely tumor work-up, and optimal patient management.
- 13 November 2026
- Published by Osterreichische Akademie der Wissenschaften, Verlag in SKINdeep
- Vol. 2, e208593
Open AccessParaneoplastic skin diseases
Paraneoplastic skin diseases (PSD) comprise a heterogeneous group of dermatoses associated with internal malignancies but are not caused by direct infiltration of the skin by tumor cells themselves. Instead, they reflect tumor-driven systemic effects mediated by hormones, growth factors, cytokines, antigens, or immune responses. A true paraneoplastic relationship is most likely when the dermatosis develops shortly before, concurrently with, or shortly after the diagnosis of the malignancy, and when both conditions follow a parallel clinical course. In this review, we revisit the concept of paraneoplastic dermatoses and propose a pragmatic classification into high-risk cutaneous paraneoplasias and low-to-moderate risk cutaneous paraneoplasias, rather than relying on the traditional distinction between “obligatory” and “facultative” entities. Particular emphasis is placed on high-risk disorders, including acrokeratosis paraneoplastica (Bazex syndrome), erythema gyratum repens, necrolytic migratory erythema, paraneoplastic pemphigus/paraneoplastic autoimmune multiorgan syndrome, hypertrichosis lanuginosa acquisita, and selected acanthotic syndromes such as malignant acanthosis nigricans, tripe palms, and florid cutaneous papillomatosis. For each entity, we summarize the characteristic clinical presentation, common tumor associations, histopathologic clues, current concepts of pathogenesis, differential diagnoses, and therapeutic implications. We also briefly address selected low-to-moderate risk paraneoplastic dermatoses, including dermatomyositis as well as Sweet syndrome, pyoderma gangrenosum, and autoimmune bullous diseases. Recognition of PSD is of major clinical importance because cutaneous signs may precede the diagnosis of cancer and thus provide an opportunity for early detection of an otherwise occult malignancy. Close interdisciplinary collaboration among dermatologists, pathologists, oncologists, and other specialists is essential for accurate diagnosis, timely tumor work-up, and optimal patient management.
- Open Access
- 26 October 2026
- Published by Springer Nature in Nature Immunology
- Vol. 27 (11) , 2293-2305
A CD4-lineage erythro–myeloid progenitor within the adult bone marrow defines an alternative pathway for macrophage generation
Tissue-resident macrophages originate from distinct developmental sources, but their adult replenishment is thought to depend exclusively on circulating monocytes. Here we identify a previously unrecognized CD4-lineage erythro–myeloid progenitor (EMPROR) in the adult bone marrow that provides an alternative pathway for macrophage generation. EMPROR cells are phenotypically and transcriptionally distinct from hematopoietic stem cells, common myeloid progenitors and monocyte precursors, lacking Csf1r and Ccr2 while expressing Cd4 and Kit . Single-cell RNA sequencing, RNA velocity analysis and lineage assays reveal macrophage, neutrophil, megakaryocytic and erythroid potential. EMPROR cells generate perivascular and tumor-associated macrophages independently of CCR2-mediated monocyte recruitment and contribute to erythroid and granulocytic lineages under inflammatory and neoplastic conditions. Transcriptomic comparisons position EMPROR cells closest to embryonic erythro–myeloid progenitors, indicating the persistence of an embryonic-like program in adult bone marrow. These findings reveal an alternative pathway of adult myelopoiesis that sustains macrophage diversity beyond the classical monocyte lineage.
- 26 October 2026
- Published by Springer Nature in Nature Immunology
- Vol. 27 (11) , 2293-2305
Open AccessA CD4-lineage erythro–myeloid progenitor within the adult bone marrow defines an alternative pathway for macrophage generation
Tissue-resident macrophages originate from distinct developmental sources, but their adult replenishment is thought to depend exclusively on circulating monocytes. Here we identify a previously unrecognized CD4-lineage erythro–myeloid progenitor (EMPROR) in the adult bone marrow that provides an alternative pathway for macrophage generation. EMPROR cells are phenotypically and transcriptionally distinct from hematopoietic stem cells, common myeloid progenitors and monocyte precursors, lacking Csf1r and Ccr2 while expressing Cd4 and Kit . Single-cell RNA sequencing, RNA velocity analysis and lineage assays reveal macrophage, neutrophil, megakaryocytic and erythroid potential. EMPROR cells generate perivascular and tumor-associated macrophages independently of CCR2-mediated monocyte recruitment and contribute to erythroid and granulocytic lineages under inflammatory and neoplastic conditions. Transcriptomic comparisons position EMPROR cells closest to embryonic erythro–myeloid progenitors, indicating the persistence of an embryonic-like program in adult bone marrow. These findings reveal an alternative pathway of adult myelopoiesis that sustains macrophage diversity beyond the classical monocyte lineage.
- Open Access
- 26 October 2026
- Published by Springer Nature in Nature Immunology
- Vol. 27 (11) , 2306-2321
The maternal–fetal interface is an early hematopoietic niche enriched in distinct erythro-myeloid progenitors
Embryonic hematopoiesis is thought to occur exclusively in the extraembryonic yolk sac before hematopoietic stem cells (HSCs) arise in the aorta–gonad–mesonephros region. Here we identify a previously unrecognized hematopoietic site at the maternal–fetal interface in mice, termed MIXER (Maternally Interfaced eXtraEmbRyonic) tissue, which develops contemporaneously with the yolk sac and exhibits robust hematopoietic activity. MIXER contains abundant hematopoietic precursors, including classical CSF1R + erythro-myeloid progenitors and a unique embryonic CD4 + CSF1R − Erythro-Myeloid PRogenitOR (eEMPROR) population. Lineage-tracing experiments demonstrate that eEMPROR cells contribute to select macrophage subpopulations during fetal development, primarily in the perivascular space. Notably, early human placental villi, before HSC emergence, also harbor CD4 + nucleated erythrocytes, indicating a conserved hematopoietic role for the maternal–fetal interface. These findings establish MIXER as an anatomically distinct niche for embryonic hematopoiesis and expand the developmental map of blood cell emergence in mammals.
- 26 October 2026
- Published by Springer Nature in Nature Immunology
- Vol. 27 (11) , 2306-2321
Open AccessThe maternal–fetal interface is an early hematopoietic niche enriched in distinct erythro-myeloid progenitors
Embryonic hematopoiesis is thought to occur exclusively in the extraembryonic yolk sac before hematopoietic stem cells (HSCs) arise in the aorta–gonad–mesonephros region. Here we identify a previously unrecognized hematopoietic site at the maternal–fetal interface in mice, termed MIXER (Maternally Interfaced eXtraEmbRyonic) tissue, which develops contemporaneously with the yolk sac and exhibits robust hematopoietic activity. MIXER contains abundant hematopoietic precursors, including classical CSF1R + erythro-myeloid progenitors and a unique embryonic CD4 + CSF1R − Erythro-Myeloid PRogenitOR (eEMPROR) population. Lineage-tracing experiments demonstrate that eEMPROR cells contribute to select macrophage subpopulations during fetal development, primarily in the perivascular space. Notably, early human placental villi, before HSC emergence, also harbor CD4 + nucleated erythrocytes, indicating a conserved hematopoietic role for the maternal–fetal interface. These findings establish MIXER as an anatomically distinct niche for embryonic hematopoiesis and expand the developmental map of blood cell emergence in mammals.
- Open Access
- 30 September 2026
- Published by Springer Nature in hautnah
- Vol. 25 (3) , 87-89
Tor! Tor! Tor!
- 30 September 2026
- Published by Springer Nature in hautnah
- Vol. 25 (3) , 87-89
Open AccessTor! Tor! Tor!
- Open Access
- 21 July 2026
- Published by Osterreichische Akademie der Wissenschaften, Verlag in SKINdeep
- Vol. 2, e199609
Cutaneous graft-versus-host disease: From acute reactions to chronic sequelae
Graft-versus-host disease (GVHD) is a frequent immune-mediated complication following allogeneic hematopoietic stem cell transplantation (HSCT), caused by a fundamental function of the immune system – the ability to distinguish between self and non-self. As a multi-systemic disorder, GVHD is characterized by tissue inflammation and fibrosis, primarily affecting the skin and mucosal surface, gastrointestinal tract, liver, and lungs. Given the potential involvement of multiple organs, a wide spectrum of clinical manifestations may be observed. Since cutaneous and mucosal manifestations are not only the most frequent finding in GVHD, but often the earliest and most clinically apparent, dermatologists play a critical role in early recognition and diagnosis. The cutaneous involvement can be complex and diagnostically challenging. This review aims to provide a comprehensive overview of the diverse skin manifestations in acute and chronic GVHD to facilitate a correct and timely diagnosis. Furthermore, we summarize current therapeutic options for GVHD subtypes to support appropriate treatment and optimize clinical outcomes.
- 21 July 2026
- Published by Osterreichische Akademie der Wissenschaften, Verlag in SKINdeep
- Vol. 2, e199609
Open AccessCutaneous graft-versus-host disease: From acute reactions to chronic sequelae
Graft-versus-host disease (GVHD) is a frequent immune-mediated complication following allogeneic hematopoietic stem cell transplantation (HSCT), caused by a fundamental function of the immune system – the ability to distinguish between self and non-self. As a multi-systemic disorder, GVHD is characterized by tissue inflammation and fibrosis, primarily affecting the skin and mucosal surface, gastrointestinal tract, liver, and lungs. Given the potential involvement of multiple organs, a wide spectrum of clinical manifestations may be observed. Since cutaneous and mucosal manifestations are not only the most frequent finding in GVHD, but often the earliest and most clinically apparent, dermatologists play a critical role in early recognition and diagnosis. The cutaneous involvement can be complex and diagnostically challenging. This review aims to provide a comprehensive overview of the diverse skin manifestations in acute and chronic GVHD to facilitate a correct and timely diagnosis. Furthermore, we summarize current therapeutic options for GVHD subtypes to support appropriate treatment and optimize clinical outcomes.
- Open Access
A Conserved Chromatin-Driven Checkpoint Defines Late Macrophage Maturation Independent of Tissue Specialization
Macrophage identity is widely viewed as a product of ontogeny and tissue-specific imprinting. Here, we identify a conserved, chromatin-driven maturation checkpoint that operates independently of initial lineage commitment and broadly across tissue contexts. Using long-term bone marrow-derived macrophage cultures, we uncover a late-stage transition characterized by coordinated transcriptional and epigenomic remodeling. Integration with in vivo developmental, tissue-resident, and monocyte-repopulation datasets demonstrates that this program is conserved across ontogenies, tissues, species, and experimental systems, revealing a previously unrecognized stage of macrophage maturation. Functionally, late maturation preserves core macrophage activities while promoting lysosomal expansion and fundamentally rewiring innate immune responsiveness. Mature macrophages display enhanced stimulus-specific responses to interferons and microbial danger signals, coupled to increased metabolic and inflammatory competence while restricting interferon-induced transcriptional memory. Together, our findings identify late macrophage maturation as a conserved regulatory checkpoint that reprograms the logic of innate immune responsiveness through chromatin remodeling shaping innate immune function.
Open AccessA Conserved Chromatin-Driven Checkpoint Defines Late Macrophage Maturation Independent of Tissue Specialization
Macrophage identity is widely viewed as a product of ontogeny and tissue-specific imprinting. Here, we identify a conserved, chromatin-driven maturation checkpoint that operates independently of initial lineage commitment and broadly across tissue contexts. Using long-term bone marrow-derived macrophage cultures, we uncover a late-stage transition characterized by coordinated transcriptional and epigenomic remodeling. Integration with in vivo developmental, tissue-resident, and monocyte-repopulation datasets demonstrates that this program is conserved across ontogenies, tissues, species, and experimental systems, revealing a previously unrecognized stage of macrophage maturation. Functionally, late maturation preserves core macrophage activities while promoting lysosomal expansion and fundamentally rewiring innate immune responsiveness. Mature macrophages display enhanced stimulus-specific responses to interferons and microbial danger signals, coupled to increased metabolic and inflammatory competence while restricting interferon-induced transcriptional memory. Together, our findings identify late macrophage maturation as a conserved regulatory checkpoint that reprograms the logic of innate immune responsiveness through chromatin remodeling shaping innate immune function.
- Open Access
- 6 July 2026
- Published by Wiley in Pigment Cell & Melanoma Research
- Vol. 39 (4) , e70105
Heme Oxygenase‐1 Differentially Controls Pigmentation in Physiological and Pathological Melanogenesis
Melanogenesis is a defining feature of melanocyte biology and influences melanoma pathogenesis; however, tumor‐specific regulators of this process remain incompletely understood. Here, we investigate how heme oxygenase‐1 (HO‐1) regulates pigmentation in malignant and homeostatic contexts. Using B16‐F10 melanoma cells engineered to express varying levels of HO‐1, we show that HO‐1 abundance correlates with pigmentation intensity and tyrosinase activity, without affecting transcription of core melanogenesis genes. Under pigment‐inducing conditions, HO‐1 inversely regulates intracellular melanin retention and pigment export, with inhibition of melanosome transfer confirming a role for HO‐1 in melanosome trafficking and secretion. Co‐culture experiments reveal that stromal HO‐1 promotes melanoma pigmentation through paracrine effects on tyrosinase expression. Transcriptomic analyses of human melanoma datasets show that HMOX1 expression correlates with pathways related to melanosome acidification, copper homeostasis, and lysosomal transport rather than classical melanogenic programs. In contrast, HO‐1 is dispensable in the non‐malignant melanocytic conditions tested here—murine iPSC‐derived melanocytes during differentiation and Melan‐A melanocytes. Together, these findings identify HO‐1 as a context‐dependent regulator of melanoma pigmentation and a potential selective target for modulating pigmentation‐dependent tumor traits.
- 6 July 2026
- Published by Wiley in Pigment Cell & Melanoma Research
- Vol. 39 (4) , e70105
Open AccessHeme Oxygenase‐1 Differentially Controls Pigmentation in Physiological and Pathological Melanogenesis
Melanogenesis is a defining feature of melanocyte biology and influences melanoma pathogenesis; however, tumor‐specific regulators of this process remain incompletely understood. Here, we investigate how heme oxygenase‐1 (HO‐1) regulates pigmentation in malignant and homeostatic contexts. Using B16‐F10 melanoma cells engineered to express varying levels of HO‐1, we show that HO‐1 abundance correlates with pigmentation intensity and tyrosinase activity, without affecting transcription of core melanogenesis genes. Under pigment‐inducing conditions, HO‐1 inversely regulates intracellular melanin retention and pigment export, with inhibition of melanosome transfer confirming a role for HO‐1 in melanosome trafficking and secretion. Co‐culture experiments reveal that stromal HO‐1 promotes melanoma pigmentation through paracrine effects on tyrosinase expression. Transcriptomic analyses of human melanoma datasets show that HMOX1 expression correlates with pathways related to melanosome acidification, copper homeostasis, and lysosomal transport rather than classical melanogenic programs. In contrast, HO‐1 is dispensable in the non‐malignant melanocytic conditions tested here—murine iPSC‐derived melanocytes during differentiation and Melan‐A melanocytes. Together, these findings identify HO‐1 as a context‐dependent regulator of melanoma pigmentation and a potential selective target for modulating pigmentation‐dependent tumor traits.
- Open Access
- 22 June 2026
- Published by Medical Journals Sweden AB in Acta Dermato-Venereologica
- Vol. 106
Organ Involvement and Treatment Response across Cutaneous Sarcoidosis Subtypes
Cutaneous sarcoidosis presents with diverse morphologies, yet comparative data on systemic involvement, disease course and treatment response across subtypes remain limited. We conducted a 2-centre cross-sectional study including patients with histologically confirmed sarcoidosis identified through ICD codes, stratified into patients with and without cutaneous involvement and further by cutaneous subtype. Demographics, extracutaneous organ involvement, treatment response, clinical course and the organ leading to initial diagnosis were analysed. Among 125 patients (median age 53 years; 57% female), 99 had cutaneous sarcoidosis and 26 had no skin involvement. All major subtypes of cutaneous sarcoidosis were represented: plaque (39), papular (19), scar (15), subcutaneous (13) and lupus pernio (4); erythema nodosum (9) represented acute disease. Papular sarcoidosis (19) showed the mildest systemic involvement. Lymph nodes (64%) and lungs (48%) were most frequently affected with subtype specific variation. Skin lesions led to diagnosis in 78% of cases. Remission with topical therapy was rare (11%), whereas systemic glucocorticoids (21%) and other immunosuppressants (37%) showed higher response rates; sirolimus (11%), hydroxychloroquine (10%) and TNF inhibitors (8%) were most effective. Relapse occurred in 40% and 46% required long-term systemic therapy. Cutaneous sarcoidosis subtypes differ markedly in systemic involvement, treatment response and disease course, supporting biological heterogeneity and the need for individualized management.
- 22 June 2026
- Published by Medical Journals Sweden AB in Acta Dermato-Venereologica
- Vol. 106
Open AccessOrgan Involvement and Treatment Response across Cutaneous Sarcoidosis Subtypes
Cutaneous sarcoidosis presents with diverse morphologies, yet comparative data on systemic involvement, disease course and treatment response across subtypes remain limited. We conducted a 2-centre cross-sectional study including patients with histologically confirmed sarcoidosis identified through ICD codes, stratified into patients with and without cutaneous involvement and further by cutaneous subtype. Demographics, extracutaneous organ involvement, treatment response, clinical course and the organ leading to initial diagnosis were analysed. Among 125 patients (median age 53 years; 57% female), 99 had cutaneous sarcoidosis and 26 had no skin involvement. All major subtypes of cutaneous sarcoidosis were represented: plaque (39), papular (19), scar (15), subcutaneous (13) and lupus pernio (4); erythema nodosum (9) represented acute disease. Papular sarcoidosis (19) showed the mildest systemic involvement. Lymph nodes (64%) and lungs (48%) were most frequently affected with subtype specific variation. Skin lesions led to diagnosis in 78% of cases. Remission with topical therapy was rare (11%), whereas systemic glucocorticoids (21%) and other immunosuppressants (37%) showed higher response rates; sirolimus (11%), hydroxychloroquine (10%) and TNF inhibitors (8%) were most effective. Relapse occurred in 40% and 46% required long-term systemic therapy. Cutaneous sarcoidosis subtypes differ markedly in systemic involvement, treatment response and disease course, supporting biological heterogeneity and the need for individualized management.
- Open Access
- 21 May 2026
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 223 (7)
CSF1R-dependent CD169-positive macrophages locally constrain melanoma growth in the skin
Macrophages in the skin reside in multiple distinct layers and perform various functions. Here, we show that CD169+ macrophages reside in the hypodermis and comprise the major skin myeloid cell population in the steady state. In a syngeneic melanoma model, CD169+ macrophages encapsulate growing melanomas and directly suppress their growth. CSF1R blockade depleted CD169+ macrophages in tumors and resulted in unrestrained growth. This local containment of tumor growth in the skin was independent of CD169+ subcapsular sinus macrophages in the tumor-draining lymph node and did not require B or T cells. Intravital imaging revealed engulfment and ingestion of live tumor cells by CD169+ macrophages. This phagocytosis did not require the phosphatidylserine receptor MERTK. CD169+ macrophages are also enriched in the hypodermis in skin biopsies from healthy human skin and melanoma. These data identify tissue-resident CD169+ macrophages as a potential cellular target to achieve innate immune containment and reinforce adaptive immune control of tumors.
- 21 May 2026
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 223 (7)
Open AccessCSF1R-dependent CD169-positive macrophages locally constrain melanoma growth in the skin
Macrophages in the skin reside in multiple distinct layers and perform various functions. Here, we show that CD169+ macrophages reside in the hypodermis and comprise the major skin myeloid cell population in the steady state. In a syngeneic melanoma model, CD169+ macrophages encapsulate growing melanomas and directly suppress their growth. CSF1R blockade depleted CD169+ macrophages in tumors and resulted in unrestrained growth. This local containment of tumor growth in the skin was independent of CD169+ subcapsular sinus macrophages in the tumor-draining lymph node and did not require B or T cells. Intravital imaging revealed engulfment and ingestion of live tumor cells by CD169+ macrophages. This phagocytosis did not require the phosphatidylserine receptor MERTK. CD169+ macrophages are also enriched in the hypodermis in skin biopsies from healthy human skin and melanoma. These data identify tissue-resident CD169+ macrophages as a potential cellular target to achieve innate immune containment and reinforce adaptive immune control of tumors.
- Open Access
A scRNA-seq atlas of chronic inflammatory skin diseases
Inflammatory skin diseases (ISDs) affect up to 25% of the global population. Yet, large-scale comparative single-cell RNA-sequencing (scRNA-seq) analyses between ISDs are still missing. Here, we integrated scRNA-seq datasets spanning 27 skin diseases from 50 studies, comprising over 2 million cells from 441 samples. Using the healthy skin cell atlas as reference, we could build a robust ISD atlas that enabled us to differentiate universal inflammatory signatures and disease-specific ones. This highlighted, for example, a shared gene program between keratinocytes in atopic dermatitis and parapsoriasis, not present in cutaneous T-cell lymphoma, confirms the plasticity of Th17 cells throughout ISDs, defines specific macrophage signatures in acne, and reveals a yet undescribed role of mural cells in ISDs. This demonstrates the power of the ISD atlas as a resource to resolve disease-specific immune mechanisms. The complete atlas is available through an interactive online portal at https://isd-atlas.derma.meduniwien.ac.at.
Open AccessA scRNA-seq atlas of chronic inflammatory skin diseases
Inflammatory skin diseases (ISDs) affect up to 25% of the global population. Yet, large-scale comparative single-cell RNA-sequencing (scRNA-seq) analyses between ISDs are still missing. Here, we integrated scRNA-seq datasets spanning 27 skin diseases from 50 studies, comprising over 2 million cells from 441 samples. Using the healthy skin cell atlas as reference, we could build a robust ISD atlas that enabled us to differentiate universal inflammatory signatures and disease-specific ones. This highlighted, for example, a shared gene program between keratinocytes in atopic dermatitis and parapsoriasis, not present in cutaneous T-cell lymphoma, confirms the plasticity of Th17 cells throughout ISDs, defines specific macrophage signatures in acne, and reveals a yet undescribed role of mural cells in ISDs. This demonstrates the power of the ISD atlas as a resource to resolve disease-specific immune mechanisms. The complete atlas is available through an interactive online portal at https://isd-atlas.derma.meduniwien.ac.at.